# Yunpeng Yang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yunpeng-yang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,814 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 49 |
| i10-index | 160 |
| Last Known Institution | Sun Yat-sen University |
| OpenAlex ID | https://openalex.org/A5023899283 |
| ORCID iD | 0000-0001-5163-0940 |
| Works | 370 |

## Researcher papers

- [Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/gemcitabine-plus-cisplatin-versus-fluorouracil-plus-cisplatin-in-recurrent-or/)
- [Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials](https://scholariq.org/papers/camrelizumab-shr-1210-alone-or-in-combination-with-gemcitabine-plus-cisplatin/)
- [Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/camrelizumab-versus-placebo-in-combination-with-gemcitabine-and-cisplatin-as/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy](https://scholariq.org/papers/ebv-driven-lmp1-and-ifn-up-regulate-pd-l1-in-nasopharyngeal-carcinoma/)
- [Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer](https://scholariq.org/papers/comprehensive-genomic-profiling-identifies-novel-genetic-predictors-of-response/)
- [Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-recurrent-or/)
- [Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer](https://scholariq.org/papers/expression-of-programmed-death-ligand-1-on-tumor-cells-varies-pre-and-post/)
- [Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition](https://scholariq.org/papers/hepatitis-b-virus-reactivation-in-cancer-patients-with-positive-hepatitis-b/)
- [Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma](https://scholariq.org/papers/systemic-inflammation-score-predicts-postoperative-prognosis-of-patients-with/)
- [Re-biopsy confers survival benefit through directing salvage treatment for patients failing prior EGFR-TKIs](https://scholariq.org/papers/re-biopsy-confers-survival-benefit-through-directing-salvage-treatment-for/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Sun Yat-sen University](https://scholariq.org/institutions/sun-yat-sen-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.